Actively Recruiting

Phase Not Applicable
Age: 18Years - 60Years
FEMALE
NCT05401175

Hematopoietic Stem Cell-containing Autologous Blood Transfusion for Bone Marrow Protection in Patients With Cervical Cancer

Led by Chongqing University Cancer Hospital · Updated on 2023-05-01

40

Participants Needed

1

Research Sites

259 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The aim of this project is to promote the reconstruction of haematopoietic function after chemoradiotherapy for cervical cancer with the innovative use of autologous haematopoietic containing stem cell blood transfusion support.To explore the effect of stored hemopoietic stem cell support therapy on bone marrow protection after concurrent chemoradiotherapy, in order to promote its clinical application.

CONDITIONS

Official Title

Hematopoietic Stem Cell-containing Autologous Blood Transfusion for Bone Marrow Protection in Patients With Cervical Cancer

Who Can Participate

Age: 18Years - 60Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 18 and 60 years
  • Have indications for radiotherapy and chemotherapy for cervical cancer
  • Pathological diagnosis of squamous, adenocarcinoma, or adenosquamous carcinoma
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 1 or less
  • Expected survival time of more than 3 months
  • Pre-menopausal women or post-menopausal for at least 12 months with negative serum pregnancy test
  • Agree to use effective contraception during the study and for 6 months after treatment
  • Voluntarily agree to participate, sign informed consent, and can complete study procedures and follow-up
Not Eligible

You will not qualify if you...

  • Diagnosis of bone marrow disease
  • Central nervous system, soft meningeal, bone, or bone marrow metastases by imaging or pathology
  • Severe cardiac insufficiency
  • Previous allogeneic stem cell or organ transplantation
  • Active bleeding or autoimmune thrombocytopenic purpura
  • Contraindications to radiochemotherapy
  • Positive for HIV
  • Acute or chronic active hepatitis B or C infection
  • History of gastrointestinal perforation or fistula, intestinal obstruction, inflammatory bowel disease, extensive bowel resection, Crohn's disease, ulcerative colitis, or chronic diarrhea within 6 months
  • Unexplained intra-abdominal pneumoperitoneum

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Chongqing University Cancer Hospital

Chongqing, Chongqing Municipality, China, 400030

Actively Recruiting

Loading map...

Research Team

D

Dongling Zou, M.D.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here